Comparisons of Urinary Bladder Responses to Common Antimuscarinics Reveals Unique Effects of Darifenacin

Vineesha Veer; Russ Chess-Williams; Christian Moro

Comparisons of Urinary Bladder Responses to Common Antimuscarinics Reveals Unique Effects of Darifenacin - Beyond the Abstract

Vineesha Veer, Russ Chess-Williams, Christian Moro^*

^*Corresponding author for this work

Research output: Contribution to journal › Online Resource › Research

Abstract

About 16-21% of patients suffer from overactive bladder (OAB) symptoms.1,2 The first line pharmaceutical treatments for OAB are antimuscarinics, with the most recent novel antimuscarinic for this purpose being approved by the US Food and Drug Administration in 2008.

Original language	English
Journal	UroToday
Publication status	Published - 22 May 2025

Access to Document

https://www.urotoday.com/recent-abstracts/pelvic-health-reconstruction/overactive-bladder/160363-comparisons-of-urinary-bladder-responses-to-common-antimuscarinics-reveals-unique-effects-of-darifenacin-beyond-the-abstract.htmlLicence: Free to read

1 Article

Comparisons of urinary bladder responses to common antimuscarinics reveals unique effects of darifenacin
Veer, V., Chess-Williams, R. & Moro, C., 20 Feb 2025, In: Frontiers in Physiology. 16, p. 1-9 9 p., 1534517.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

2 Downloads (Pure)

Cite this

Veer, V., Chess-Williams, R., & Moro, C. (2025). Comparisons of Urinary Bladder Responses to Common Antimuscarinics Reveals Unique Effects of Darifenacin - Beyond the Abstract. UroToday. https://www.urotoday.com/recent-abstracts/pelvic-health-reconstruction/overactive-bladder/160363-comparisons-of-urinary-bladder-responses-to-common-antimuscarinics-reveals-unique-effects-of-darifenacin-beyond-the-abstract.html

@article{e70eb26d77c7442994080d6e794b1a3d,

title = "Comparisons of Urinary Bladder Responses to Common Antimuscarinics Reveals Unique Effects of Darifenacin - Beyond the Abstract",

abstract = "About 16-21% of patients suffer from overactive bladder (OAB) symptoms.1,2 The first line pharmaceutical treatments for OAB are antimuscarinics, with the most recent novel antimuscarinic for this purpose being approved by the US Food and Drug Administration in 2008.",

author = "Vineesha Veer and Russ Chess-Williams and Christian Moro",

year = "2025",

month = may,

day = "22",

language = "English",

journal = "UroToday",

}

Veer, V , Chess-Williams, R & Moro, C 2025, 'Comparisons of Urinary Bladder Responses to Common Antimuscarinics Reveals Unique Effects of Darifenacin - Beyond the Abstract', UroToday. <https://www.urotoday.com/recent-abstracts/pelvic-health-reconstruction/overactive-bladder/160363-comparisons-of-urinary-bladder-responses-to-common-antimuscarinics-reveals-unique-effects-of-darifenacin-beyond-the-abstract.html>

TY - JOUR

T1 - Comparisons of Urinary Bladder Responses to Common Antimuscarinics Reveals Unique Effects of Darifenacin - Beyond the Abstract

AU - Veer, Vineesha

AU - Chess-Williams, Russ

AU - Moro, Christian

PY - 2025/5/22

Y1 - 2025/5/22

N2 - About 16-21% of patients suffer from overactive bladder (OAB) symptoms.1,2 The first line pharmaceutical treatments for OAB are antimuscarinics, with the most recent novel antimuscarinic for this purpose being approved by the US Food and Drug Administration in 2008.

AB - About 16-21% of patients suffer from overactive bladder (OAB) symptoms.1,2 The first line pharmaceutical treatments for OAB are antimuscarinics, with the most recent novel antimuscarinic for this purpose being approved by the US Food and Drug Administration in 2008.

M3 - Online Resource

JO - UroToday

JF - UroToday

ER -

Comparisons of Urinary Bladder Responses to Common Antimuscarinics Reveals Unique Effects of Darifenacin - Beyond the Abstract

Abstract

Access to Document

Related Research Outputs

Cite this